Literature DB >> 768379

Artifactual plaque formation in vitro and in vivo to passive transfer of specific antibody.

A V Muchmore, I Koski, N Dooley, R M Blaese.   

Abstract

The localized hemolysis in gel (LHG) assay for antibody-secreting cells was used to evaluate antibody production in heterologous erythrocyte-immunized cultures of human peripheral blood lymphocytes supplemented with 10% human plasma. Antigen-specific plaques were detected in such cultures and the number of plaques varied with different lymphocyte donors and were inhibited by heat killing the cultures before assay. However, plaque number varied directly with the number of immunizing erythrocytes added to the cultures and inversely with the number of lymphocytes added. Maximum plaque production occurred within 10 min of initiation of the cultures and occurred in the absence of any lymphoid cells. Absorption of the plasma used as culture supplement with the immunizing erythrocyte resulted in complete abrogation of subsequent specific plaque formation. Mice previously passively immunized with high titered anti-erythrocyte antibody had large numbers of plaques detected 30 min after i.v. immunization with the appropriate erythrocyte. These plaques detected by LHG are the result of carry-over of aggregates of antibody-coated erythrocytes and subsequent release of this antibody in the LHG assay and are not the result of active antibody synthesis. This "pseudoplaque" production may lead to the false interpretation of plaque formation as indicating active synthesis of antibody in vivo and in vitro where such experiments are carried out in immune animals or with antibody containing serum culture supplements.

Entities:  

Mesh:

Year:  1976        PMID: 768379

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Characterization of suppressor T cells for antibody production by chicken spleen cells. I. Antigen-induced suppressor cells are CT8+, TcR1+ (gamma delta) T cells.

Authors:  P Quere; M D Cooper; G J Thorbecke
Journal:  Immunology       Date:  1990-12       Impact factor: 7.397

2.  Immunoregulation in humans: control of antitetanus toxoid antibody production after booster immunization.

Authors:  R H Stevens; A Saxon
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

3.  Polyclonal activation of bone-marrow-derived lymphocytes from human peripheral blood measured by a direct plaque-forming cell assay.

Authors:  A S Fauci; K R Pratt
Journal:  Proc Natl Acad Sci U S A       Date:  1976-10       Impact factor: 11.205

4.  Polyclonal and antigen-specific B-cell responses in patients with common variable immunodeficiency.

Authors:  S G Pahwa; M K Hoffman; R N Pahwa; R A Good
Journal:  J Clin Immunol       Date:  1982-07       Impact factor: 8.317

5.  Antigen-specific induction and regulation of antibody synthesis in cultures of human peripheral blood mononuclear cells.

Authors:  M K Hoffmann
Journal:  Proc Natl Acad Sci U S A       Date:  1980-02       Impact factor: 11.205

6.  Decreased in vitro humoral immune responses in aged humans.

Authors:  S G Pahwa; R N Pahwa; R A Good
Journal:  J Clin Invest       Date:  1981-04       Impact factor: 14.808

7.  Pseudoplaque formation by cytophilic immunoglobulins in the sera of lupus patients as measured using reverse haemolytic plaque assay.

Authors:  M Okubo; K Kamata; T Uchiyama
Journal:  Clin Exp Immunol       Date:  1982-05       Impact factor: 4.330

8.  Canine bronchoalveolar cells: antigen-presenting macrophages are Ia-positive, lymphocytes are of non-B lineage.

Authors:  J C Wulff; S C Springmeyer; H J Deeg; R Storb
Journal:  Blut       Date:  1983-11

9.  Use of a human plaque-forming cell assay to study peripheral blood bursa-equivalent cell activation and excessive suppressor cell activity in humoral immunodeficiency.

Authors:  H G Herrod; R H Buckley
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

10.  Severe combined immunodeficiency disease: a model of T-cell dysfunction.

Authors:  H M Dosch; J W Lee; E W Gelfand; J A Falk
Journal:  Clin Exp Immunol       Date:  1978-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.